Premium
Genistein and endothelial function in postmenopausal women with metabolic syndrome
Author(s) -
Irace Concetta,
Marini Herbert,
Bitto Alessandra,
Altavilla Domenica,
Polito Francesca,
Adamo Elena Bianca,
Arcoraci Vincenzo,
Minutoli Letteria,
Benedetto Antonino,
Vieste Giacoma,
Gregorio Cesare,
Gnasso Agostino,
Corrao Salvatore,
Licata Giuseppe,
Squadrito Francesco
Publication year - 2013
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12139
Subject(s) - medicine , brachial artery , adiponectin , genistein , endocrinology , placebo , metabolic syndrome , homocysteine , endothelial dysfunction , diabetes mellitus , insulin resistance , blood pressure , alternative medicine , pathology
Background Previous data have suggested that genistein could exert beneficial effects on endothelial function and on predictors of cardiovascular risk in healthy postmenopausal women. In a randomized clinical trial, we studied the effects of genistein on endothelial function in postmenopausal women with metabolic syndrome ( MS ). Methods Twenty postmenopausal women with MS , according to modified NCEP ‐ ATP III criteria were randomly assigned to receive placebo or genistein (54 mg/day) for 6 months, along with a Mediterranean‐style diet. Postmenopausal women without MS ( n = 15), served as controls. The primary goal was the assessment of endothelial function by flow‐mediated vasodilation ( FMD ) of brachial artery; moreover, time‐to‐peak dilation in the FMD response has been evaluated. Secondary outcomes were fasting glucose, fasting insulin, total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, visfatin, adiponectin and homocysteine blood levels. Data on adverse events were also recorded. Results After 6 months of treatment, FMD at 50s and peak FMD significantly increased in genistein recipients compared with placebo. Moreover, genistein significantly decreased the blood levels of total cholesterol, triglycerides, homocysteine and visfatin compared with placebo, while blood adiponectin levels were increased. Genistein recipients neither experienced more side–adverse effects than placebo nor discontinued the study. Conclusions Six months of treatment with genistein effectively improves brachial artery flow‐mediated vasodilation in postmenopausal women with metabolic syndrome.